Tehran University of Medical Sciences Basic & Clinical Cancer Research 2228-6527 11 1 2019 01 02 16 26 EN Elmira Ebrahimi Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran Reza Shirkoohi Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. AND Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran Maryam Abiri Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. AND Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Solmaz Sabeghi Kawsar Human Genetics Research Center, Tehran, Iran. Kiyana Sadat Fatemi Kawsar Human Genetics Research Center, Tehran, Iran. Samira Dabagh Bagheri Kawsar Human Genetics Research Center, Tehran, Iran. Sirous Zeinali Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran AND Kawsar Human Genetics Research Center, Tehran, Iran Saeid Amanpour Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran AND Vali-e-Asr Reproductive Health Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2018 11 17 2018 12 23 Background: Pre-implantation Genetic Diagnosis (PGD)  has recently been introduced as a reproductive choice for individuals who carry a disease-causing BRCA1/2 mutation. Since this technology has not yet been launched for patients at the Cancer Institute of Imam Khomeini Hospital harboring gene mutations that predispose patients to breast cancer, this study aimed to introduce a PGD-based model using a single cell lymphocyte instead of an embryonic blastomere. Methods: Two affected and unrelated women with a known mutation in BRCA1/2 were enrolled in this study. Each patient (together with her siblings) was considered as an embryo derived from a hypothetical couple. Blood samples were collected from these individuals as well as their parents. Linkage analysis was performed. Following this process, a mutation-free individual and a mutation carrier was selected from the first and second family, respectively. A single lymphocyte was then extracted from their freshly taken peripheral blood, and afterwards Nested Multiplex PCR was performed. Results: PGD confirmed that the individual from the first family is free of a mutation and the second one is a pathogenic mutation carrier. Conclusions: Our results suggested that PGD is a viable choice to offer to families with "Hereditary Breast Cancer Syndrome", who have been diagnosed with a known pathogenic mutation. Our introduced model can be used as a possible option by other laboratories that are planning to launch this technology. https://bccr.tums.ac.ir/index.php/bccrj/article/view/309